Delix Therapeutics, a Boston MA-based preclinical neuroscience company, raised $70M in Series A funding.
The round was led by Artis Ventures, RA Capital Management, and founding investor OMX Ventures, with participation from Apeiron, Bail Capital, Casa Verde Capital, Dolby Family Ventures, Negev Capital, Noetic Fund, Ocama Partners, Palo Santo, Presight Capital, PsyMed Ventures, R2, Re.Mind Capital, Saya Bio, Vertical Venture Partners, WPSS, and other family investment funds.
The company intends to use the funds to advance its novel non-hallucinatory, take-home, neuroplasticity-promoting candidates into clinical trials to better treat mental illness and other brain disorders at scale, and continue to grow its team.
Co-founded by Nick Haft & David E. Olson, Delix provides a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to treat mental health disorders at scale. The company’s compounds are small molecules capable of rapidly inducing structural and functional neural changes in targeted areas of the brain. Its discovery engine has produced nearly 1,000 novel compounds to-date, with several potential clinical development candidates identified. The company’s most advanced compounds, which have been profiled in Nature and Cell, are non-hallucinogenic analogs of clinically-validated first-generation psychedelics like psilocybin, LSD, DMT, and MDMA. Delix’s orally bioavailable compounds preserve the long-lasting beneficial rewiring of neurons without the risk, safety liabilities, and other patient access barriers inherent to first- and second-generation psychedelics. DLX-1 and DLX-7, the first two development candidates to emerge from Delix, are currently undergoing pre-IND safety and toxicology studies to enable clinical trials to begin in 2022.